NCNA Clinical trials

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Published September 03, 2025 at 12:00 PM

(NASDAQ:NCNA) EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”).